Safety and Efficacy of 25 and 50 mg Doses of Proellex® in Treating the Recurrence of Uterine Fibroid Symptoms
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Subjects with symptomatic uterine fibroids will be enrolled and will receive daily oral study
medication for 4 months. This will be followed by a 6 month off-drug interval until there is
a return of significant symptomatology. If they experience symptoms of a certain severity,
the subject will enter a second 4 month treatment cycle and then a follow-up period.